Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q4 EPS of ($0.46), $0.06 better than the analyst estimate of ($0.52).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.